Sionna Therapeutics Inc. (SION) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Sionna Therapeutics Inc. (NASDAQ: SION) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.73 (-3.62% 1D, market cap $175.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SION ranks #683 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SION carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.3%. By comparison, TRDA (Entrada Therapeutics Inc.) holds a E grade (16/100 RQD, P/E N/A, ROIC -35.0%, cap $176.6M) and ORMP (Oramed Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -7.8%, cap $171.0M). Among the 5-stock peer group, SION leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).
Per SION's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002036042), Sionna Therapeutics Inc. generated $249.1M in revenue (+26.1% YoY), -$75.3M in net income, and -$66.7M in free cash flow against $326.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.5 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While SION currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.38) and Max Pain ($3.92) forces dealer call-delta covering toward $57.72.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Sionna Therapeutics Inc. (SION) dropped -3.62% to $3.73, trading at 2% of its 52-week range ($3.55 – $54.97). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
The Clinical Trial Vanguard report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Investing.com South Africa report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +26.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SION today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SION. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Sionna Therapeutics Inc. (SION) ranks #683 by composite RQD confidence (33/100, grade E) and #589 by equity capitalization ($175.0M). Within this direct 5-issuer industry benchmark cohort, SION leads on earnings valuation at N/A trailing P/E, while ORMP leads on capital efficiency and profitability with -7.8% ROIC and 0.7% gross margin. ANTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with SION at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SION
ACTIVE
Sionna Therapeutics Inc. | E | 33/100 | — | — | -28.3% | -3.62% | $175.0M | Benchmark Subject |
| TRDA Entrada Therapeutics Inc. | E | 16/100 | — | — | -35.0% | +12.68% | $176.6M | /trda-vs-sion → |
| ORMP Oramed Pharmaceuticals Inc. | E | 33/100 | — | 0.7% | -7.8% | -2.68% | $171.0M | /ormp-vs-sion → |
| ANTX AN2 Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -3.97% | $170.9M | /antx-vs-sion → |
| ADAG Adagene Inc. | E | 25/100 | — | — | -35.0% | -8.76% | $165.8M | /adag-vs-sion → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sionna Therapeutics Inc. (SION) reported GAAP revenue of $249.1M (+26.1% vs. FY2024 revenue of $197.6M ) , GAAP net income of -$75.3M, operating cash flow of -$66.3M, and free cash flow of -$66.7M (-26.2% YoY). On the balance sheet, SION closed FY2025 with $326.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $249.1M | -$75.3M | -$66.3M | -$66.7M | $326.0M | — |
| FY2024 (FY) | 2024-12-31 | $197.6M | -$61.7M | -$52.8M | -$52.8M | $185.8M | — |
As of 2026-11-03, Sionna Therapeutics Inc. (NASDAQ: SION) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.73 (-3.62% 1D, market cap $175.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SION ranks #683 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SION carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.3%. By comparison, TRDA (Entrada Therapeutics Inc.) holds a E grade (16/100 RQD, P/E N/A, ROIC -35.0%, cap $176.6M) and ORMP (Oramed Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -7.8%, cap $171.0M). Among the 5-stock peer group, SION leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).
Per SION's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002036042), Sionna Therapeutics Inc. generated $249.1M in revenue (+26.1% YoY), -$75.3M in net income, and -$66.7M in free cash flow against $326.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
SION last traded at $3.73 (-3.62% on volume of 655,451 shares), positioning the stock -30.67% below its 50-day simple moving average ($5.38) and -87.46% below its 200-day simple moving average ($29.75). Across its 52-week range of $3.55 to $54.97, SION sits at the 0.4% percentile with a 14-day RSI of 33.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.26 to $4.20).
Sionna Therapeutics Inc. (SION) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.73 (-3.62% 1D, market capitalization $175.0M).
. (SION) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The source data states a market capitalization of $0.2B. Product lines, customer base, and revenue model are — Reported revenue for FY 2025 and FY 2024 is — in each period, .
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Sionna Therapeutics Inc. (SION) reported $249.1M in annual revenue (up from $197.6M in FY2024, +26.1% YoY) and -$75.3M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($197.6M revenue, -$61.7M net income) through FY2025, SION scaled operating cash flow to -$66.3M and free cash flow to -$66.7M, backed by $326.0M in total assets against $0 in total debt.
Upstream suppliers, downstream customers, and sector correlations beyond the Beta of 1.0 are — Investors should note that the absence of graph data is itself a gap, not evidence of isolation from the sector.
Real-time company headlines, analyst actions, and sector developments for Sionna Therapeutics Inc. (SION) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
The Clinical Trial Vanguard report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Investing.com South Africa report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Australia report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.
Long SION at $3.87 targeting $4.64. Reported cash rose from $37.8M to $58.5M while the forensic pillar scores Altman Z 2.5, indicating a balance sheet not acutely stressed by the data provided.. Institutional whale score is 3/20 and the risk/reward vs. the $3.55 52-week low is skewed heavily in favor of bulls.
@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
I respect the product at Sionna Therapeutics Inc., but the stock at $3.87 is a different story. Zero reported revenue, FY 2025 operating loss of -$89.0M, FCF of -$66.7M, and ROIC of -28.3% leave the Fundamental Cash Engine pillar at 7/20.. FCF yield is 0.0% and RQD sits at 33/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: